GB1056192A - Pharmaceutical compositions containing catalase - Google Patents

Pharmaceutical compositions containing catalase

Info

Publication number
GB1056192A
GB1056192A GB97765A GB97765A GB1056192A GB 1056192 A GB1056192 A GB 1056192A GB 97765 A GB97765 A GB 97765A GB 97765 A GB97765 A GB 97765A GB 1056192 A GB1056192 A GB 1056192A
Authority
GB
United Kingdom
Prior art keywords
mannitol
catalase
hexol
pharmaceutical compositions
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB97765A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sincorep S A
Original Assignee
Sincorep S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR959675A external-priority patent/FR3531M/en
Application filed by Sincorep S A filed Critical Sincorep S A
Publication of GB1056192A publication Critical patent/GB1056192A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Catalase is stabilized by a hexol, which may be added to it at any stage of its isolation or purification. The hexol may be mannitol, dulcitol, sorbitol, or inositol. In an example, ox liver is comminuted with an aqueous solution of mannitol. The mixture is filtered, catalase being precipitated from the filtrate by the addition of acetone. The crude catalase containing mannitol is dissolved in aqueous mannitol solution, filtered, and the filtrate is dialysed. The catalase precipitate obtained by dialysis is redissolved in buffer solution at pH 7.3 and is allowed to crystallize. The crystals are redissolved in aqueous mannitol solution and lyophilized.ALSO:Pharmaceutical compositions for use in the treatment of arthrosis, hepatitis, lipomatosis, uricaemia, and hypercholestarolaemia contain or consist of catalase stablized by a hexol. The hexol may be derived from a sugar. Specified hexols are mannitol, dulcitol, sorbitol, and inositol. The active substance may be used in the lyophilised form, or with one or more carriers or excipients. The pharmaceutical compositions may be in the form of injectable solutions or suppositories.
GB97765A 1964-01-08 1965-01-08 Pharmaceutical compositions containing catalase Expired GB1056192A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR959675A FR3531M (en) 1964-01-08 1964-01-08 New drug based on catalase.
FR959674A FR1484614A (en) 1964-01-08 1964-01-08 Catalase stabilization process

Publications (1)

Publication Number Publication Date
GB1056192A true GB1056192A (en) 1967-01-25

Family

ID=26205263

Family Applications (1)

Application Number Title Priority Date Filing Date
GB97765A Expired GB1056192A (en) 1964-01-08 1965-01-08 Pharmaceutical compositions containing catalase

Country Status (5)

Country Link
BE (1) BE657602A (en)
DE (1) DE1252610B (en)
FR (1) FR1484614A (en)
GB (1) GB1056192A (en)
LU (1) LU47683A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0477143A2 (en) * 1990-08-30 1992-03-25 Idi Farmaceutici S.P.A. Pharmaceutical composition having a cicatrising effect
EP2648721A1 (en) * 2011-01-31 2013-10-16 LUCOLAS-M.D. Ltd. Combinations of aromatase inhibitors and antioxidants

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR8202M (en) * 1968-10-31 1970-09-14
WO2003014339A2 (en) * 2001-08-07 2003-02-20 Novozymes, A/S Carbohydrates and polyols for dissolving protein crystals

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0477143A2 (en) * 1990-08-30 1992-03-25 Idi Farmaceutici S.P.A. Pharmaceutical composition having a cicatrising effect
EP0477143A3 (en) * 1990-08-30 1993-02-24 Idi Farmaceutici S.P.A. Pharmaceutical composition having a cicatrising effect
EP2648721A1 (en) * 2011-01-31 2013-10-16 LUCOLAS-M.D. Ltd. Combinations of aromatase inhibitors and antioxidants
EP2648721B1 (en) * 2011-01-31 2018-09-19 LUCOLAS-M.D. Ltd. Combinations of aromatase inhibitors and antioxidants
US10835540B2 (en) 2011-01-31 2020-11-17 Lucolas-M.D. Ltd. Pharmaceutical use

Also Published As

Publication number Publication date
FR1484614A (en) 1967-06-16
LU47683A1 (en) 1965-03-02
DE1252610B (en) 1967-10-26
BE657602A (en) 1965-06-24

Similar Documents

Publication Publication Date Title
GB1097544A (en) Phenoxy-substituted alkanols
GB1303408A (en)
GB1056192A (en) Pharmaceutical compositions containing catalase
BE768724A (en) PROCESS FOR THE PREPARATION OF CHROME (III) OXIDE LOW IN SULFUR
GB1097103A (en) Improvements in or relating to combine harvesters
DK316288D0 (en) ACARIDID MEDICINE
ES398016A1 (en) Process for isolating a fibrin-stabilizing factor
AT288853B (en) Process for the treatment of pulp waste liquors by fluidized bed combustion
GB1062434A (en) Process for isolating -antitrypsin
ES353533A1 (en) Tetanus vaccine and process for preparing it
GB1100443A (en) 17ª‡-chloroethynyl-13ª‰-ethylgonenolone
ES373657A1 (en) Di-hydro triazine derivatives and processes for their manufacture
CH471091A (en) Process for the preparation of N-Benzyl-N ', N' '- dimethylguanidine
ES304963A1 (en) Melamine purification method. (Machine-translation by Google Translate, not legally binding)
GB1271984A (en) Hydroxylated steroids
GB1395929A (en) Thioureas
USD140349S (en) Design for a lighter case or similar article
GB523667A (en) Improved manufacture of barium carbonate
SE7907251L (en) NEW METHYL-L-PIPERIDINOL-4 ESTERS AND SETTING TO MAKE THESE AND PHARMACEUTICAL COMPOSITIONS, CONTAINING THESE ESTERS
GB845823A (en) Stabilised compositions comprising therapeutic imine derivatives and the preparation thereof
CH448099A (en) Process for the preparation of 1-naphthyl-acetic acid esters of N, N'-di- (B-hydroxyethyl) piperazine
AU407297B2 (en) Concentration of phosphoric acids and concurrent separation of impurities
GB547518A (en) Improvements in or relating to compositions capable of inhibiting agglutination of hemolysis in blood
GB1036283A (en) A substituted amide
GB1210063A (en) Immunogenic preparations and a process for their production